Sign up
Log in
Novocure wins CE mark for Optune Pax in locally advanced pancreatic cancer treatment
Share
Listen to the news
Novocure wins CE mark for Optune Pax in locally advanced pancreatic cancer treatment
  • Novocure’s Optune Pax won CE Mark clearance for adults with locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel.
  • PANOVA-3 showed median overall survival of 16.2 months versus 14.2 months on chemotherapy alone, supporting the EU authorization.
  • The company plans to launch Optune Pax in Germany in the coming weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260630829863) on June 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved